#1 Clinical Trials Search in Europe

Milademetan

Milademetan is an investigational drug being studied in clinical trials for various types of cancer, particularly acute myeloid leukemia (AML) and advanced solid tumors. As an oral MDM2 inhibitor, it works by targeting a specific protein involved in cancer cell growth. This article summarizes key information from several clinical trials evaluating milademetan’s safety, efficacy, and potential as a new cancer therapy.

Table of Contents

What is Milademetan?

Milademetan, also known as DS-3032b or RAIN-32, is an experimental drug being studied for the treatment of various types of cancer[1]. It belongs to a class of drugs called MDM2 inhibitors, which are designed to target specific proteins involved in cancer growth[2].

How Does Milademetan Work?

Milademetan works by blocking a protein called MDM2. This protein normally helps control the levels of another important protein called p53, which is known as the “guardian of the genome” because it helps prevent cancer by stopping damaged cells from dividing. In some cancers, there’s too much MDM2, which can prevent p53 from doing its job. By blocking MDM2, milademetan allows p53 to become active again and help fight cancer cells[1][2].

What Conditions Does Milademetan Treat?

Milademetan is being studied for the treatment of several types of cancer, including:

  • Advanced solid tumors: These are cancers that form solid masses in the body, such as in the lungs, breast, or colon[1].
  • Lymphomas: Cancers that start in cells of the immune system[1].
  • Acute Myeloid Leukemia (AML): A type of blood cancer that affects the bone marrow[2].
  • Myelodysplastic Syndrome (MDS): A group of disorders where the bone marrow doesn’t produce enough healthy blood cells[2].
  • Advanced or metastatic breast cancer: Specifically for patients with certain genetic mutations (GATA3 mutations)[3].

Clinical Trials and Research

Milademetan is currently being studied in various clinical trials to determine its safety and effectiveness. These trials are testing the drug:

  • Alone in different doses and schedules[1].
  • In combination with other cancer drugs like azacitidine for leukemia[2].
  • With quizartinib for a specific type of AML[4].
  • Combined with atezolizumab for solid tumors with specific genetic changes[5].
  • With fulvestrant for breast cancer patients with GATA3 mutations[3].

Researchers are looking at how well the drug works, how safe it is, and how it affects the body (pharmacokinetics and pharmacodynamics)[1][2].

How is Milademetan Administered?

Milademetan is taken orally as capsules. The dosage and schedule can vary depending on the specific study and condition being treated. Some common dosing schedules include:

  • Daily for 3-14 days, followed by a rest period[1].
  • Three consecutive days every two weeks[5].

The capsules come in different strengths (5 mg, 20 mg, 80 mg, and 200 mg) and are sometimes combined to achieve the right dose[1].

Potential Side Effects

As with any medication, milademetan can cause side effects. In clinical trials, researchers are closely monitoring for:

  • Changes in blood cell counts
  • Liver function abnormalities
  • Gastrointestinal issues (nausea, vomiting, diarrhea)
  • Fatigue
  • Effects on heart rhythm (QT prolongation)[6]

It’s important to note that not all patients will experience these side effects, and the severity can vary. Researchers are working to understand and manage these potential side effects[1][2].

Drug Interactions

Milademetan interacts with enzymes in the liver called CYP3A4. This means it can potentially interact with other medications that affect these enzymes. Specific studies have looked at interactions with drugs like itraconazole and posaconazole (antifungal medications)[7]. Patients should always inform their healthcare providers about all medications they are taking.

Future Research and Potential

Milademetan is still in the early stages of research, but it shows promise for treating various types of cancer, especially those where the p53 pathway is disrupted. Ongoing and future studies will help determine:

  • Which patients are most likely to benefit from the drug
  • The best dosing schedules and combinations with other treatments
  • Long-term safety and effectiveness

As research continues, milademetan may become an important new option in the fight against cancer[1][2][3].

Aspect Details
Drug Name Milademetan (also known as DS-3032b)
Drug Class Oral MDM2 inhibitor
Primary Indications Acute Myeloid Leukemia (AML), Advanced Solid Tumors
Administration Oral capsules, various dosing schedules
Key Clinical Trials NCT01877382, NCT02319369, NCT03552029, NCT03671564, NCT06090318
Combination Studies With azacitidine, quizartinib, atezolizumab, low-dose cytarabine
Primary Outcomes Safety, tolerability, maximum tolerated dose, pharmacokinetics
Secondary Outcomes Objective response rate, progression-free survival, overall survival
Common Side Effects Nausea, fatigue, decreased appetite, changes in blood cell counts
Current Status Investigational; not yet approved for general use

FAQ

  • What is milademetan and how does it work? Milademetan is an oral MDM2 inhibitor being investigated as a potential cancer treatment. It works by targeting the MDM2 protein, which is involved in cancer cell growth and survival. By inhibiting MDM2, milademetan may help stop or slow the growth of cancer cells.
  • What types of cancer is milademetan being studied for? Milademetan is being studied primarily for acute myeloid leukemia (AML) and various advanced solid tumors. Some trials are also looking at its potential for treating myelodysplastic syndrome (MDS) and lymphomas.
  • How is milademetan administered in clinical trials? Milademetan is given orally as capsules. The dosing schedules vary between trials, but often involve taking the medication daily for a certain number of days, followed by a rest period, in cycles.
  • What are some common side effects observed with milademetan? Common side effects reported in clinical trials include nausea, fatigue, decreased appetite, and changes in blood cell counts. The trials are closely monitoring for any adverse events to determine the drug's safety profile.
  • Is milademetan being studied in combination with other treatments? Yes, several clinical trials are investigating milademetan in combination with other cancer treatments. For example, it's being studied with azacitidine for AML, and with atezolizumab for certain solid tumors.

Ongoing Clinical Trials on Milademetan

  • Study of Milademetan and Fulvestrant for Patients with Advanced or Metastatic Breast Cancer with GATA3 Mutation, ER-Positive, HER2-Negative

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • MDM2 inhibitor: A type of drug that blocks the activity of the MDM2 protein, which is involved in cancer cell growth and survival. By inhibiting MDM2, these drugs may help stop or slow the growth of cancer cells.
  • Acute Myeloid Leukemia (AML): A type of cancer that affects the blood and bone marrow, characterized by the rapid growth of abnormal white blood cells that interfere with the production of normal blood cells.
  • Myelodysplastic Syndrome (MDS): A group of disorders caused by poorly formed or dysfunctional blood cells, which can lead to problems like anemia and may progress to acute myeloid leukemia in some cases.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body. This helps researchers understand how the body processes the drug and determine appropriate dosing.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a reduction in dosage. Identifying DLTs helps determine the maximum tolerated dose of a drug.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects. This is often determined during the dose escalation phase of clinical trials.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment. It includes both complete responses and partial responses to the treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • CDKN2A: A gene that provides instructions for making several proteins involved in cell growth and division. Mutations in this gene are associated with increased cancer risk.
  • FLT3-ITD mutation: A genetic mutation found in some cases of acute myeloid leukemia that affects the FLT3 gene, potentially making the leukemia more aggressive and harder to treat.

References

  1. https://clinicaltrials.gov/study/NCT01877382
  2. https://clinicaltrials.gov/study/NCT02319369
  3. https://clinicaltrials.gov/study/NCT05932667
  4. https://clinicaltrials.gov/study/NCT03552029
  5. https://clinicaltrials.gov/study/NCT06090318
  6. https://clinicaltrials.gov/study/NCT05758818
  7. https://clinicaltrials.gov/study/NCT03614455